Privately-held Polyrizon Ltd has reported preclinical data showing that its proprietary technology potentially reduces the risk of infection with Human coronavirus and may also prevent COVID-19.
- Medigus Ltd’s (NASDAQ:MDGS) owns 33.24% of Polyrizon’s share capital.
- Polyrizon’s technology is designed to safely prevent allergens and virus intrusion through the upper airways and eye cavities. It includes a bio-gel applied topically and can be formulated both for wet and dry administration.
- Data from Polyrizon’s cell-culture study that lasted a month confirms that the product works dose-dependent to reduce cells’ infection effectively.
- Polyrizon tested a few prototypes of its lead platform against COVID-19. In these studies, the products demonstrated high efficacy over the controlled groups by preventing coronavirus from affecting epithelial host cells and inhibiting cell death.
- In addition, the product shows a favorable safety profile in cell toxicity studies.
- Polyrizon is planning clinical trials for its products subject to receipt of regulatory approvals. The first efficacy results are currently expected within the next 12 months.
- Price Action: MDGS shares are up 15.9% at $1.75 during the market session on the last check Friday.